Chembio Diagnostics, Inc. Reports Third Quarter Financial Results

MEDFORD, N.Y., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (“POC”) diagnostic tests for infectious diseases, today reported financial results for the three and nine months ended September 30, 2015.

John J. Sperzel III, Chief Executive Officer, stated, “Chembio continues to focus on the following three business areas: Sexually Transmitted Diseases (“STD”), Fever Diseases, and Technology Collaborations. During the third quarter of 2015, the company achieved significant milestones in each of these areas, which created additional value in our products and partnerships. With respect to STD, the launch of our SURE CHECK® HIV 1/2 self-testing kits in Europe was a great success, and we have received orders that will bring our total sales of these kits to approximately $1.0 million in 2015. Concerning Fever Diseases, the Paul G. Allen Ebola Program selected DPP® as a platform for the first ever POC multiplex fever disease panel, granting Chembio $2.1 million for the 12-month development of this groundbreaking test. And, in the area of Technology Collaborations, our successful feasibility work with DPP® as a diagnostic platform for a specific type of cancer allowed us to advance to the development stage with additional committed funding from our DPP® Cancer partner.”

Help employers find you! Check out all the jobs and post your resume.

Back to news